Nasonex Dosing for Post-Nasal Drip

Standard Dosing Regimen

• The American Academy of Otolaryngology recommends Nasonex (mometasone furoate) 2 sprays per nostril once daily (200 mcg total daily dose) for post-nasal drip in adults and adolescents ≥12 years, and 1 spray per nostril once daily (100 mcg total daily dose) for children ages 2-11 years 1
• The standard dosing regimen of 2 sprays (50 mcg each) per nostril once daily for a total of 200 mcg/day in adults and children ≥12 years has been validated in multiple clinical trials demonstrating significant improvement in nasal symptoms including post-nasal drip compared to placebo 2

Evidence Supporting This Dosing

• The European Position Paper on Rhinosinusitis demonstrates that mometasone furoate 200 mcg twice daily (400 mcg/day) produced significant improvements in post-nasal drip symptoms in post-viral rhinosinusitis patients, with the twice-daily regimen showing greater efficacy than once-daily dosing 2
• For routine post-nasal drip management, the standard once-daily 200 mcg dose is appropriate and FDA-approved 1

When to Consider Higher Dosing

• For severe or refractory post-nasal drip, particularly in the context of nasal polyps or severe inflammatory conditions, consider increasing to 2 sprays per nostril twice daily (400 mcg total daily dose) 1, 2

Administration Technique to Maximize Efficacy

• Using the contralateral hand technique, holding the spray bottle in the opposite hand relative to the nostril being treated, aiming slightly away from the nasal septum, reduces epistaxis risk by four times 1, 3
• Do not close the opposite nostril during administration 3

Timeline for Symptom Relief

• Counsel patients that onset of action may be delayed approximately 12 hours, with maximal efficacy reached in days to weeks 1, 4
• Regular daily use rather than as-needed dosing is essential to maintain symptom control 1, 4

Safety Profile and Common Side Effects

• The most common adverse events include headache, viral infection, pharyngitis, epistaxis (nosebleeds), and cough—all generally mild to moderate in severity 1
• Mometasone furoate is safe for long-term use, with no suppression of the hypothalamic-pituitary-adrenal axis at recommended doses, even with continuous administration 3
• Studies demonstrate no effect on growth in children at recommended doses compared to placebo 3

Contraindications

• Mometasone is contraindicated in patients with hypersensitivity to mometasone or any component of the formulation 1, 3

Duration of Treatment

• Continue treatment for a minimum of 8-12 weeks to allow adequate time for symptomatic relief and proper assessment of therapeutic benefit 3
• Long-term daily use is safe and appropriate when clinically indicated, as intranasal corticosteroids do not cause rhinitis medicamentosa (rebound congestion) unlike topical decongestants 3

First‑Line Intranasal Corticosteroid Therapy for Post‑Nasal Drip with Inferior Turbinate Swelling

Recommended Agents and Dosing

• Mometasone furoate 200 µg once daily (2 sprays per nostril) or fluticasone propionate 200 µg once daily are advised as the first‑line intranasal corticosteroid for patients with post‑nasal drip and inferior turbinate swelling. 5

Treatment Duration and Monitoring

• Treat for a minimum of 8–12 weeks before evaluating response; stopping treatment earlier than 8 weeks is linked to therapeutic failure. 5
• Symptom relief typically begins ~12 hours after the first dose, with maximal efficacy reached over several days to weeks. 6

Administration Technique (Essential for Efficacy)

• Use the contralateral‑hand technique – hold the spray bottle in the hand opposite the nostril being treated, aim toward the lateral nasal wall, keep the head upright, breathe gently, do not occlude the opposite nostril, and shake the bottle before each use. This method reduces the risk of epistaxis by approximately fourfold compared with the ipsilateral technique. 7, 6
• Counsel patients to use the spray daily rather than on an as‑needed basis to maintain symptom control. 6

Adjunctive Nasal Saline Irrigation

• Perform high‑volume nasal saline irrigation (isotonic or hypertonic) as an adjunct; irrigation should be done before the corticosteroid spray to avoid washing out the medication. 7, 6
• High‑volume irrigation is significantly more effective than saline spray for mechanically removing mucus and inflammatory mediators. 7

Dose Escalation for Refractory Symptoms

• If symptoms persist after 4–8 weeks on standard dosing, increase to 400 µg/day (2 sprays per nostril twice daily). Higher doses show a trend toward greater efficacy but increase epistaxis risk (relative risk 2.06; 95 % CI 1.20–3.54), with most bleeding being mild. 8, 6

Short‑Term Use of Nasal Decongestants

• For severe nasal obstruction that limits corticosteroid penetration, a short course (≤4 weeks) of oxymetazoline applied 5 minutes before the steroid spray can improve drug delivery without causing rebound congestion; decongestants should not be used alone or for longer than 4 weeks to avoid rhinitis medicamentosa. 9, 10

Safety Profile

• Long‑term daily use of intranasal corticosteroids at recommended doses is safe, with no evidence of hypothalamic‑pituitary‑adrenal axis suppression; the most common adverse effect is mild epistaxis. 8